Antitumor activity of interleukin-1 alpha and cisplatin in a murine model system.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Archives of Otolaryngology - Head and Neck Surgery

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 7840928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic enhancement by interleukin-1 α of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice

  2004cited by this paper
• The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

  1992cited by this paper
• A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.

  1991cited by this paper
• Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha.

  1991cited by this paper
• Acute hemorrhagic necrosis of tumors induced by interleukin-1 alpha: effects independent of tumor necrosis factor.

  1991cited by this paper
• Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazole.

  1990cited by this paper
• The effect of adrenalectomy and dexamethasone on interleukin-1 alpha induced responses in RIF-1 tumours.

  1990cited by this paper
• Cytokines and endothelial cell biology.

  1990cited by this paper
• Synergistic antitumor activity of etoposide and human interleukin-1 alpha against human melanoma cells.

  1989cited by this paper
• 31P-nuclear magnetic resonance studies of the effect of recombinant human interleukin 1 alpha on the bioenergetics of RIF-1 tumors.

  1989cited by this paper
• Recombinant human interleukin 1 alpha is cytotoxic for and increases surface expression of HLA-A,B,C antigens of a human hepatoma cell line, PLC/PRF/5.

  1989cited by this paper
• Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors.

  1988cited by this paper
• Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

  1987cited by this paper
• Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor

  1986cited by this paper
• There is more than one interleukin 1.

  1986cited by this paper
• Human interleukin 1 is a cytocidal factor for several tumor cell lines.

  1985cited by this paper
• Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion.

  1984cited by this paper
• Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells

  1983cited by this paper
• The functional relationship of the interleukins

  1980cited by this paper
• Cell kinetics in vivo and in vitro for C3H/He spontaneous mammary tumors.

  1977cited by this paper
• POTENTIATION OF THE T-LYMPHOCYTE RESPONSE TO MITOGENS

  1972cited by this paper

• Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer

  2020influential citation
• Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells

  2019cites this paper
• Interleukin-1 signaling contributes to the anti-tumor efficacy of Cetuximab in head and neck squamous cell carcinoma

  2018cites this paper
• Chemical Carcinogenesis in Epidermis on α Expression of IL-1 Carcinogenesis : The Effect of Constitutive , Innate Immunity , and Skin α IL-1

  2003cites this paper
• IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis.

  2003cites this paper
• Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer.

  2003cites this paper
• Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA array

  2002cites this paper
• Intramuscular electroporation delivery of IFN-α gene therapy for inhibition of tumor growth located at a distant site

  2001cites this paper
• Effects of the novel alphav integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8.

  2000cites this paper
• Combination Gene Therapy for Salivary Gland Cancer

  1998cites this paper
• Biologic Activity of Interleukin 1 (IL‐1) Alpha in Patients with Refractory Malignancies

  1998cites this paper
• A new immunocompetent murine model for oral cancer.

  1997cites this paper
• Modulation of cisPlatin cytotoxicity by interleukin-1 alpha and resident tumor macrophages.

  1997cites this paper